Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glaucoma | 24 | 2024 | 1186 | 5.030 |
Why?
|
Glaucoma, Open-Angle | 14 | 2024 | 739 | 4.910 |
Why?
|
Intraocular Pressure | 23 | 2024 | 1294 | 3.910 |
Why?
|
Glaucoma, Angle-Closure | 9 | 2022 | 191 | 3.720 |
Why?
|
Trabeculectomy | 6 | 2024 | 174 | 3.190 |
Why?
|
Iridectomy | 6 | 2023 | 48 | 2.800 |
Why?
|
Iris | 5 | 2023 | 231 | 2.620 |
Why?
|
Laser Therapy | 6 | 2024 | 1094 | 2.340 |
Why?
|
Vision Disorders | 11 | 2024 | 1089 | 1.950 |
Why?
|
Ocular Hypertension | 5 | 2024 | 208 | 1.900 |
Why?
|
Eye Injuries | 2 | 2021 | 227 | 1.220 |
Why?
|
Visually Impaired Persons | 3 | 2022 | 78 | 1.170 |
Why?
|
Intravitreal Injections | 4 | 2024 | 385 | 1.080 |
Why?
|
Visual Fields | 9 | 2024 | 1061 | 1.020 |
Why?
|
Biological Specimen Banks | 5 | 2024 | 780 | 0.990 |
Why?
|
Siblings | 3 | 2021 | 824 | 0.970 |
Why?
|
Gonioscopy | 8 | 2021 | 155 | 0.960 |
Why?
|
Tomography, Optical Coherence | 12 | 2024 | 2923 | 0.890 |
Why?
|
Visual Acuity | 10 | 2024 | 2676 | 0.860 |
Why?
|
Medicare Part B | 1 | 2024 | 117 | 0.820 |
Why?
|
Optic Disk | 2 | 2024 | 421 | 0.820 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 664 | 0.790 |
Why?
|
Glaucoma Drainage Implants | 2 | 2021 | 107 | 0.790 |
Why?
|
Trabecular Meshwork | 2 | 2020 | 101 | 0.790 |
Why?
|
Diabetic Retinopathy | 2 | 2021 | 1276 | 0.780 |
Why?
|
Phacoemulsification | 2 | 2022 | 150 | 0.780 |
Why?
|
Lasers, Solid-State | 3 | 2018 | 176 | 0.770 |
Why?
|
Cataract | 3 | 2024 | 828 | 0.710 |
Why?
|
Corneal Endothelial Cell Loss | 1 | 2020 | 24 | 0.690 |
Why?
|
Macular Degeneration | 4 | 2022 | 1009 | 0.680 |
Why?
|
Angiogenesis Inhibitors | 2 | 2024 | 2047 | 0.640 |
Why?
|
Optic Nerve Diseases | 1 | 2021 | 342 | 0.580 |
Why?
|
Endophthalmitis | 1 | 2020 | 260 | 0.580 |
Why?
|
Endothelium, Corneal | 1 | 2020 | 215 | 0.570 |
Why?
|
Eye Proteins | 1 | 2021 | 632 | 0.570 |
Why?
|
Eye Infections, Bacterial | 1 | 2020 | 241 | 0.570 |
Why?
|
Recombinant Fusion Proteins | 2 | 2024 | 3726 | 0.550 |
Why?
|
Multifactorial Inheritance | 2 | 2024 | 1387 | 0.540 |
Why?
|
Nutrition Surveys | 3 | 2021 | 1723 | 0.540 |
Why?
|
Genome-Wide Association Study | 7 | 2024 | 12676 | 0.510 |
Why?
|
Anterior Eye Segment | 1 | 2016 | 143 | 0.500 |
Why?
|
Cytoskeletal Proteins | 1 | 2021 | 1334 | 0.490 |
Why?
|
Retinal Ganglion Cells | 5 | 2024 | 810 | 0.490 |
Why?
|
Visual Field Tests | 4 | 2024 | 411 | 0.480 |
Why?
|
Neurodegenerative Diseases | 1 | 2024 | 1085 | 0.480 |
Why?
|
Laser Coagulation | 1 | 2016 | 330 | 0.460 |
Why?
|
Registries | 4 | 2024 | 8246 | 0.440 |
Why?
|
Refractive Errors | 1 | 2015 | 148 | 0.430 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2024 | 3493 | 0.430 |
Why?
|
Diabetes Mellitus | 2 | 2022 | 5842 | 0.430 |
Why?
|
Glycoproteins | 1 | 2021 | 2203 | 0.430 |
Why?
|
Accidental Falls | 1 | 2021 | 1068 | 0.420 |
Why?
|
Cross-Sectional Studies | 17 | 2024 | 26072 | 0.410 |
Why?
|
Apocrine Glands | 1 | 2012 | 32 | 0.410 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2012 | 14 | 0.410 |
Why?
|
Angioid Streaks | 1 | 2012 | 14 | 0.410 |
Why?
|
Humans | 74 | 2024 | 761222 | 0.400 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2022 | 1186 | 0.400 |
Why?
|
Ear Neoplasms | 1 | 2012 | 118 | 0.390 |
Why?
|
Tonometry, Ocular | 5 | 2021 | 236 | 0.380 |
Why?
|
Ear Canal | 1 | 2012 | 149 | 0.380 |
Why?
|
Stents | 2 | 2021 | 3177 | 0.380 |
Why?
|
Early Diagnosis | 1 | 2016 | 1186 | 0.370 |
Why?
|
Hearing Loss | 1 | 2018 | 782 | 0.360 |
Why?
|
Sweat Gland Neoplasms | 1 | 2012 | 116 | 0.360 |
Why?
|
Mendelian Randomization Analysis | 4 | 2024 | 1010 | 0.360 |
Why?
|
United States | 17 | 2024 | 72341 | 0.360 |
Why?
|
Postural Balance | 1 | 2015 | 623 | 0.350 |
Why?
|
Tourette Syndrome | 1 | 2013 | 395 | 0.350 |
Why?
|
Aged | 24 | 2024 | 169292 | 0.330 |
Why?
|
Retrospective Studies | 20 | 2024 | 80675 | 0.330 |
Why?
|
Medicare | 3 | 2023 | 6774 | 0.330 |
Why?
|
Neural Inhibition | 1 | 2013 | 586 | 0.330 |
Why?
|
Umbilical Cord | 1 | 2010 | 178 | 0.320 |
Why?
|
Male | 41 | 2024 | 360703 | 0.320 |
Why?
|
Middle Aged | 33 | 2024 | 220858 | 0.320 |
Why?
|
Medicaid | 1 | 2022 | 2813 | 0.310 |
Why?
|
Female | 42 | 2024 | 392552 | 0.310 |
Why?
|
Cultural Diversity | 2 | 2022 | 369 | 0.310 |
Why?
|
Choroidal Neovascularization | 1 | 2012 | 364 | 0.310 |
Why?
|
Anterior Chamber | 2 | 2021 | 194 | 0.310 |
Why?
|
Pericytes | 1 | 2010 | 295 | 0.290 |
Why?
|
Anxiety | 1 | 2022 | 4569 | 0.290 |
Why?
|
Disability Evaluation | 1 | 2015 | 1834 | 0.290 |
Why?
|
Myasthenia Gravis | 1 | 2010 | 214 | 0.280 |
Why?
|
Electronic Health Records | 1 | 2024 | 4822 | 0.270 |
Why?
|
Retina | 4 | 2024 | 2656 | 0.270 |
Why?
|
Faculty, Medical | 1 | 2015 | 1205 | 0.270 |
Why?
|
Activities of Daily Living | 1 | 2015 | 2420 | 0.250 |
Why?
|
Guideline Adherence | 1 | 2015 | 2220 | 0.240 |
Why?
|
Follow-Up Studies | 9 | 2024 | 39127 | 0.230 |
Why?
|
Nerve Fibers | 3 | 2024 | 707 | 0.230 |
Why?
|
India | 4 | 2020 | 2287 | 0.210 |
Why?
|
Refraction, Ocular | 1 | 2024 | 184 | 0.210 |
Why?
|
Mitomycin | 1 | 2023 | 263 | 0.210 |
Why?
|
Prevalence | 5 | 2022 | 15721 | 0.210 |
Why?
|
Ophthalmology | 2 | 2022 | 550 | 0.210 |
Why?
|
Myopia | 1 | 2024 | 252 | 0.190 |
Why?
|
Corneal Dystrophies, Hereditary | 1 | 2021 | 62 | 0.180 |
Why?
|
Area Under Curve | 1 | 2024 | 1636 | 0.170 |
Why?
|
Risk Factors | 7 | 2024 | 74241 | 0.170 |
Why?
|
Mesenchymal Stem Cells | 1 | 2010 | 1645 | 0.170 |
Why?
|
Limbus Corneae | 1 | 2021 | 144 | 0.170 |
Why?
|
Descemet Stripping Endothelial Keratoplasty | 1 | 2021 | 112 | 0.170 |
Why?
|
Wound Healing | 1 | 2010 | 2800 | 0.160 |
Why?
|
Penetrance | 1 | 2021 | 382 | 0.160 |
Why?
|
ROC Curve | 2 | 2024 | 3584 | 0.160 |
Why?
|
Anti-Inflammatory Agents | 2 | 2024 | 1812 | 0.160 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2021 | 251 | 0.160 |
Why?
|
Adult | 17 | 2024 | 221120 | 0.160 |
Why?
|
Lasers | 1 | 2023 | 952 | 0.160 |
Why?
|
Fluorouracil | 1 | 2023 | 1642 | 0.160 |
Why?
|
Scleritis | 1 | 2019 | 96 | 0.150 |
Why?
|
International Classification of Diseases | 1 | 2024 | 915 | 0.150 |
Why?
|
Cataract Extraction | 1 | 2022 | 463 | 0.150 |
Why?
|
Cardiovascular Diseases | 1 | 2024 | 15521 | 0.150 |
Why?
|
Biometry | 1 | 2021 | 563 | 0.150 |
Why?
|
Uveitis | 1 | 2021 | 396 | 0.150 |
Why?
|
Manometry | 2 | 2020 | 453 | 0.150 |
Why?
|
Cicatrix | 1 | 2023 | 793 | 0.150 |
Why?
|
Face | 1 | 2024 | 1025 | 0.150 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 7400 | 0.150 |
Why?
|
Hearing Tests | 1 | 2018 | 121 | 0.150 |
Why?
|
Vision, Ocular | 1 | 2021 | 454 | 0.140 |
Why?
|
Microvessels | 1 | 2021 | 580 | 0.140 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3354 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12159 | 0.140 |
Why?
|
Skin | 1 | 2010 | 4473 | 0.140 |
Why?
|
Psychotropic Drugs | 1 | 2022 | 885 | 0.140 |
Why?
|
Prospective Studies | 6 | 2022 | 54437 | 0.130 |
Why?
|
Mutation | 1 | 2021 | 30004 | 0.130 |
Why?
|
Drug Costs | 1 | 2024 | 1183 | 0.130 |
Why?
|
Eyeglasses | 1 | 2016 | 138 | 0.120 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 637 | 0.120 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2024 | 1390 | 0.120 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6341 | 0.120 |
Why?
|
Postoperative Period | 1 | 2020 | 1818 | 0.120 |
Why?
|
Internship and Residency | 1 | 2015 | 5885 | 0.120 |
Why?
|
Eye | 1 | 2018 | 713 | 0.110 |
Why?
|
Treatment Outcome | 7 | 2024 | 64681 | 0.110 |
Why?
|
Sickness Impact Profile | 1 | 2015 | 299 | 0.110 |
Why?
|
Vision, Binocular | 1 | 2015 | 224 | 0.110 |
Why?
|
Remission Induction | 1 | 2019 | 2392 | 0.110 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9187 | 0.110 |
Why?
|
Academies and Institutes | 1 | 2015 | 318 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 1993 | 0.100 |
Why?
|
Pandemics | 2 | 2022 | 8663 | 0.100 |
Why?
|
Physical Stimulation | 1 | 2013 | 517 | 0.100 |
Why?
|
Emergency Service, Hospital | 2 | 2021 | 7865 | 0.100 |
Why?
|
Quality of Life | 3 | 2022 | 13367 | 0.090 |
Why?
|
Touch | 1 | 2013 | 310 | 0.090 |
Why?
|
Sex Distribution | 1 | 2016 | 2277 | 0.090 |
Why?
|
Insurance Coverage | 1 | 2022 | 1935 | 0.090 |
Why?
|
Pyridostigmine Bromide | 1 | 2010 | 32 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2023 | 5493 | 0.090 |
Why?
|
Insurance, Health | 1 | 2022 | 2493 | 0.080 |
Why?
|
Self Report | 1 | 2021 | 3727 | 0.080 |
Why?
|
Family Health | 1 | 2014 | 1254 | 0.080 |
Why?
|
Receptors, Cholinergic | 1 | 2010 | 244 | 0.080 |
Why?
|
Blood Pressure | 1 | 2024 | 8479 | 0.080 |
Why?
|
Incidence | 3 | 2021 | 21366 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2576 | 0.080 |
Why?
|
Cholinesterase Inhibitors | 1 | 2010 | 241 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2018 | 22174 | 0.080 |
Why?
|
Risk Assessment | 2 | 2024 | 24022 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2024 | 15308 | 0.070 |
Why?
|
Time Factors | 2 | 2020 | 39957 | 0.070 |
Why?
|
Biopsy, Needle | 1 | 2012 | 1624 | 0.070 |
Why?
|
Rare Diseases | 1 | 2012 | 624 | 0.070 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 694 | 0.070 |
Why?
|
Brain | 1 | 2013 | 27094 | 0.070 |
Why?
|
Cognition | 1 | 2024 | 6988 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2019 | 4190 | 0.070 |
Why?
|
Aged, 80 and over | 4 | 2024 | 58952 | 0.060 |
Why?
|
Genomics | 1 | 2021 | 5829 | 0.060 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2010 | 668 | 0.060 |
Why?
|
Morbidity | 2 | 2021 | 1751 | 0.060 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2010 | 501 | 0.060 |
Why?
|
Prednisone | 1 | 2010 | 1565 | 0.060 |
Why?
|
Axial Length, Eye | 1 | 2024 | 35 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 3590 | 0.060 |
Why?
|
Cornea | 2 | 2023 | 1327 | 0.060 |
Why?
|
Mice, Nude | 1 | 2010 | 3606 | 0.060 |
Why?
|
Comorbidity | 1 | 2018 | 10516 | 0.050 |
Why?
|
Angiopoietins | 1 | 2023 | 86 | 0.050 |
Why?
|
Depression | 1 | 2022 | 8132 | 0.050 |
Why?
|
Attention | 1 | 2013 | 2394 | 0.050 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2010 | 1625 | 0.050 |
Why?
|
Sex Factors | 1 | 2016 | 10553 | 0.050 |
Why?
|
Choroid | 1 | 2024 | 363 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4851 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7407 | 0.050 |
Why?
|
Mice, Inbred BALB C | 1 | 2010 | 6200 | 0.050 |
Why?
|
Age Factors | 1 | 2018 | 18384 | 0.050 |
Why?
|
Circadian Rhythm | 1 | 2013 | 2569 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 29688 | 0.050 |
Why?
|
Keratoplasty, Penetrating | 1 | 2021 | 143 | 0.050 |
Why?
|
Immunologic Factors | 1 | 2010 | 1589 | 0.040 |
Why?
|
Tissue Engineering | 1 | 2010 | 1866 | 0.040 |
Why?
|
Retinal Degeneration | 1 | 2024 | 414 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2010 | 6819 | 0.040 |
Why?
|
Retinal Pigment Epithelium | 1 | 2022 | 303 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2012 | 11067 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12976 | 0.030 |
Why?
|
Gender Identity | 1 | 2022 | 766 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 8998 | 0.030 |
Why?
|
Disease Progression | 2 | 2024 | 13511 | 0.030 |
Why?
|
Young Adult | 2 | 2020 | 59222 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2022 | 934 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 36415 | 0.030 |
Why?
|
Minority Groups | 1 | 2022 | 1201 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2024 | 1878 | 0.030 |
Why?
|
Language | 1 | 2024 | 1539 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2010 | 18927 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2024 | 15920 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2010 | 10423 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2024 | 2159 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 1577 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2023 | 20118 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2010 | 11512 | 0.030 |
Why?
|
Supine Position | 1 | 2013 | 205 | 0.030 |
Why?
|
Adolescent | 1 | 2020 | 88300 | 0.020 |
Why?
|
Child | 1 | 2020 | 80154 | 0.020 |
Why?
|
Hemorrhage | 1 | 2023 | 3422 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2024 | 3366 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2010 | 18222 | 0.020 |
Why?
|
Psychometrics | 1 | 2021 | 3061 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2024 | 4052 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3200 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2022 | 3453 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3840 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20588 | 0.020 |
Why?
|
Cohort Studies | 2 | 2022 | 41496 | 0.020 |
Why?
|
Software | 1 | 2023 | 4431 | 0.020 |
Why?
|
Databases, Factual | 1 | 2024 | 7965 | 0.020 |
Why?
|
Age Distribution | 1 | 2014 | 2871 | 0.020 |
Why?
|
Hospitals | 1 | 2022 | 3881 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14675 | 0.020 |
Why?
|
Animals | 2 | 2023 | 168089 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2022 | 15841 | 0.010 |
Why?
|
Health Surveys | 1 | 2014 | 4037 | 0.010 |
Why?
|
Mice | 1 | 2010 | 81330 | 0.010 |
Why?
|
Algorithms | 1 | 2023 | 14025 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9652 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10759 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2022 | 15637 | 0.010 |
Why?
|
Phenotype | 1 | 2014 | 16575 | 0.010 |
Why?
|